Ep. 345 - TAC to the Future. Plus: GSK Deal, MFN

What It Covers

BioCentury This Week covers JPMorgan Healthcare Conference takeaways, GSK's $2.2B acquisition of Wrap Therapeutics targeting food allergies, next-generation targeted protein degradation technologies including TACs and lysosomal degraders, Trump's push to codify Most Favored Nation drug pricing into legislation, and pediatric priority review voucher reauthorization progress in Congress.

Key Questions Answered

• •GSK's Wrap acquisition strategy: GSK paid $2.2B ($1.9B net of cash) for Wrap Therapeutics, a company that in-licensed its food allergy prophylaxis asset from Chinese firm JU just 13 months prior for $35M upfront plus ~$700M in milestones. The Phase 2b asset targets a dosing advantage over Xolair, with results expected within one year.
• •China-to-West asset licensing model: Western pharma companies are actively licensing and acquiring assets originating from Chinese biotechs, but geopolitical barriers make full company acquisitions of Chinese firms effectively off the table. The practical playbook is to take the asset, not the company, avoiding regulatory and political entanglement while capturing innovation.
• •TAC field expansion beyond proteasome: Next-generation targeted protein degradation now spans four distinct mechanisms: classical PROTAC E3 ligase recruitment via cereblon, new E3 ligases like TRIM21 that selectively degrade aggregated proteins while sparing monomers, lysosomal degraders targeting extracellular proteins via bispecific antibodies, and induced proximity approaches enabling phosphorylation and protein stabilization beyond degradation.
• •MFN legislation risk for small biotechs: Trump's push to codify Most Favored Nation pricing into law poses a greater threat to small biotechs than large multinationals. Private White House deals use a definition benchmarked to the second-lowest price among eight industrialized nations — public legislation could impose a stricter definition across the entire industry with no negotiated carve-outs.
• •Pediatric PRV reauthorization near completion: The House included pediatric priority review voucher reauthorization through September 30, 2029 in a government spending bill. PRVs function as a zero-taxpayer-cost mechanism transferring capital from large pharma to small biotechs developing therapies for rare pediatric diseases, and are a prerequisite for gene and cell therapy development in ultra-rare conditions.